| |
| |
|
| Insider
Information: |
Backenroth Samuel |
| Relationship: |
Chief Financial Officer |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
536,630 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$144,586 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
536,630 |
|
|
| Total
Value |
$144,586 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neubase Therapeutics Ord Shs |
NBSE |
CFO, Treasurer & Secre... |
2020-04-30 |
11,630 |
|
0 |
Premium* |
|
|
Notable Labs |
NTBL |
Chief Financial Officer |
2023-03-31 |
525,000 |
2023-03-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
8 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NTBL |
Notable Labs |
Chief Financial Officer |
• – – |
2023-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
525,000 |
525,000 |
0 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
CFO, Treasurer & Secretary |
• – – |
2020-04-30 |
4 |
B |
$6.00 |
$6,000 |
D/D |
1,000 |
11,630 |
2.74 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2017-04-10 |
4 |
B |
$0.70 |
$50,000 |
D/D |
71,429 |
212,596 |
2.74 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2016-06-20 |
4 |
B |
$2.71 |
$6,997 |
D/D |
2,468 |
141,167 |
2.74 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2016-05-23 |
4 |
B |
$3.11 |
$7,926 |
D/D |
2,500 |
138,699 |
2.74 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2016-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
130,000 |
136,199 |
0 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2015-02-06 |
4 |
B |
$6.75 |
$10,125 |
D/D |
1,500 |
6,199 |
2.74 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
CEO & VP of Bus. DevelopmentOf |
• – – |
2013-06-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,699 |
|
- |
|
8 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
